Recent 8-K filings for CORT

• May 28, 2026, 4:04 PM ET other material materiality 0.55 neutral item 5.02item 5.07item 9.01

  Corcept shareholders approve 8M-share increase to 2024 Incentive Award Plan

  Stockholders approved amendment to 2024 Incentive Award Plan, adding 8,000,000 authorized shares.

• April 30, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved

  Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.

• March 25, 2026, 7:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer

  Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

• February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B

  Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).

• February 19, 2026, 6:59 PM ET litigation materiality 0.85 negative item 8.01item 9.01

  Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents

  Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.

• January 22, 2026, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction

  Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).

• December 31, 2025, 6:59 PM ET regulatory materiality 0.78 negative item 8.01item 9.01

  FDA issues Complete Response Letter for Corcept's relacorilant NDA in hypercortisolism

  FDA concluded benefit-risk assessment unfavorable without additional effectiveness evidence.

• November 4, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M

  Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.

• October 14, 2025, 7:59 PM ET other material materiality 0.35 neutral item 1.02item 9.01

  Corcept terminates distribution agreement with Optime Care, effective Jan 8, 2026

  Notice of termination of Distribution Services Agreement with Optime Care given Oct 10, 2025; effective Jan 8, 2026.

• October 6, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01

  Director Gillian Cannon resigns from Corcept board; consulting agreement signed

  Dr. Gillian Cannon resigned from the Board effective October 10, 2025, with no disagreement over operations or policies.

• September 10, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026

  FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.

• July 31, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M

  Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.

• July 14, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer

  NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.

• June 16, 2025, 7:59 PM ET other material materiality 0.10 neutral item 5.07item 9.01

  Corcept shareholders elect nine directors, ratify Ernst & Young, approve executive comp at annual meeting

  All nine director nominees elected with substantial support; David Mahoney received 62.7M for, 14.7M withheld.

• May 5, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates

  Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.

• March 31, 2025, 7:59 PM ET other material materiality 0.95 positive item 8.01item 9.01

  Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly

  30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.

• March 3, 2025, 6:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025

  FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).

• February 26, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M

  Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).

• December 30, 2024, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Corcept submits NDA for relacorilant to treat Cushing's syndrome

  NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.

• October 30, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results

  Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.

• July 29, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M

  Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.

• May 23, 2024, 7:59 PM ET other materiality 0.50 neutral item 5.02item 5.07item 9.01

  Corcept Therapeutics shareholders approve 2024 Incentive Award Plan adding 8M new shares

  2024 Plan replaces 2012 plan; total shares authorized = 8M new + 4,073,955 carryover + lapsed awards.

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M

  Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.78 · Most common event earnings

14 positive 2 negative 7 neutral

source · CORT on sec.gov